Clinical Trial Update: Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating durvalumab as monotherapy or in combination with novel agents for unresectable Stage III non-small cell lung cancer has completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Stage III Non-small Cell Lung Cancer, Unresectable | Phase 2 | Status: COMPLETED | Results posted: 2024-10-08